Despite over a decade of cystic fibrosis (CF) microbiome research, much remains to be
learned about the overall composition, metabolic activities, and pathogenicity of the …

Culture-independent studies have revealed that chronic lung infections in persons with
cystic fibrosis (pwCF) are rarely limited to one microbial species. Interactions among …

Recent molecular methodologies have demonstrated a complex microbial ecosystem in
cystic fibrosis (CF) airways, with a wide array of uncommon microorganisms co-existing with …

Introduction: Cystic fibrosis (CF) lung disease is characterized by chronic cycles of
pulmonary infection, inflammation, and mucus obstruction, beginning early in life, and …

Long-term follow-up of microbiome development and alterations in relation to progression of
lung disease and treatment is recommended. Moreover, integrating this information with …

Cystic fibrosis (CF) is a fatal genetic disease characterized by chronic lung infections due to
aberrant mucus production and the inability to clear invading pathogens. The traditional …

Cystic fibrosis (CF) is a genetic disease with mutational changes leading to profound
dysbiosis, both pulmonary and intestinal, from a very young age. This dysbiosis plays an …

Interspecies interactions can drive the emergence of unexpected microbial phenotypes that
are not observed when studying monocultures. The cystic fibrosis (CF) lung consists of a …

Antimicrobial therapies against cystic fibrosis (CF) lung infections are largely aimed at the
traditional, well-studied CF pathogens such as Pseudomonas aeruginosa and Burkholderia …

Current therapy for cystic fibrosis (CF) focuses on minimizing the microbial community and
the host's immune response through the aggressive use of airway clearance techniques …